Product
Tigilanol Tiglate
Aliases
EBC-46, tigilanol tiglate
4 clinical trials
3 indications
Indication
Head and Neck CancerIndication
MelanomaIndication
Soft Tissue SarcomaClinical trial
A Phase II, Open Label, Single Arm Study To Assess The Efficacy Of Intratumoral Tigilanol Tiglate In Various Head And Neck Solid MalignanciesStatus: Recruiting, Estimated PCD: 2025-08-01
Clinical trial
A Phase IIb, Multicentre, Open Label Study to Evaluate the Effectiveness, Safety and Tolerability of Intratumoural Tigilanol Tiglate in Adult Participants With Stage IIIB to IV M1c MelanomaStatus: Terminated, Estimated PCD: 2022-07-18
Clinical trial
A Phase Ib/IIa, Dose-escalation Study to Evaluate the Safety, Tolerability, and Preliminary Effectiveness of Intratumoural Tigilanol Tiglate in Combination With Intravenous Pembrolizumab in Adults With Stage IIIb to IV M1c-melanomaStatus: Terminated, Estimated PCD: 2022-07-12
Clinical trial
A Phase IIa Open Label Study Evaluating the Preliminary Efficacy of Intratumoural Tigilanol Tiglate in Advanced and/or Metastatic Soft Tissue Sarcoma of the Extremities and Body Wall.Status: Recruiting, Estimated PCD: 2024-07-01